Tan Y., Sementino E., Menges C.W., Kukuyan A.-M., Peri S., Cheung M., Khazak V., Ross E., Fox L.A., Jhanwar S.C., Ramanathan C., Flores R.M., Balachandran S., Testa J.R. Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in malignant mesothelioma. Clin Cancer Res. Epub Nov. 17, 2020.
Gary J., Simmons J.K., Xu J., Zhang S., Peat T., Watson N., Gamache B., Zhang K., Kovalchuk A., Michalowski A., Chen J.-Q., Thaiwong T., Kiupel M., Gaikwad S., Etienne M., Simpson R.M., DuBois W., Testa J.R., Mock B. Genetic inhibition of mTOR delays thymic Pre-T LBL tumorigenesis: implications for therapeutic intervention. Mol Cancer Ther 10:2221-32, 2020. PMID: 32747423
Tan Y., Sementino E., Liu Z., Cai K.Q., Testa J.R. Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis. Sci Rep. 10:15837, 2020. PMCID: PMC7522078
Kukuyan A.-M., Sementino E., Kadariya Y., Menges C.W., Cheung M., Tan Y., Cai K.Q., Slifker M.J., Peri S., Klein-Szanto A.J., Rauscher F.J. III, Testa J.R. Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models. Cancer Res. 79:4113-23, 2019. PMCID: PMC6697648
Cai W., Su L., Liao L., Liu Z.Z., Langbein L., Dulaimi E., Testa J.R., Uzzo R.G., Zhong Z., Jiang W., Yan Q., Zhang Q., Yang H. PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth. Nat Commun. 10:5800, 2019. PMCID: PMC6925188
Rao S., Peri S., Hoffmann J., Cai K.Q., Harris B., Rhodes M., Connolly D.C., Testa J.R., Wiest D.L. RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance. PLoS One 14:e0222392, 2019. PMCID: PMC6776433
Peng H., Prokop J., Karar J., Park K., Cao L., Harbour J.W., Bowcock A.M., Malkowicz S.B., Cheung M., Testa J.R., Rauscher F.J. Familial and somatic BAP1 mutations inactivate ASXL1/2-mediated allosteric regulation of BAP1 deubiquitinase by targeting multiple independent domains. Cancer Res. 78:1200-13, 2018. PMCID: PMC6167014
Sementino E., Menges C.W., Kadariya Y., Peri S., Xu J., Liu Z., Wilkes R.G., Cai K.Q., Rauscher F.J. 3rd, Klein-Szanto A.J., Testa J.R. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol. 233:8952-61, 2018. PMCID: PMC6168364
Walpole S., Pritchard A.L., Cebulla C.M., Pilarski R., Stautberg M., Davidorf F.H., de la Fouchardière A., Cabaret O., Golmard L., Stoppa-Lyonnet D., Garfield E., Njauw C.N., Cheung M., Turunen J.A., Repo P., Järvinen R.S., van Doorn R., Jager M.J., Luyten G.P.M., Marinkovic M., Chau C., Potrony M., Höiom V., Helgadottir H., Pastorino L., Bruno W., Andreotti V., Dalmasso B., Ciccarese G., Queirolo P., Mastracci L., Wadt K., Kiilgaard J.F., Speicher M.R., van Poppelen N., Kilic E., Al-Jamal R.T., Dianzani I., Betti M., Bergmann C., Santagata S., Dahiya S., Taibjee S., Burke J., Poplawski N., O'Shea S.J., Newton-Bishop J., Adlard J., Adams D.J., Lane A.M., Kim I., Klebe S., Racher H., Harbour J.W., Nickerson M.L., Murali R., Palmer J.M., Howlie M., Symmons J., Hamilton H., Warrier S., Glasson W., Johansson P., Robles-Espinoza C.D., Ossio R., de Klein A., Puig S., Ghiorzo P., Nielsen M., Kivelä T.T., Tsao H., Testa J.R., Gerami P., Stern M.H., Paillerets B.B., Abdel-Rahman M.H., Hayward N.K. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J Natl Cancer Inst. 110:1328-41, 2018. PMCID: PMC6292796... Expand
Testa J.R. (ed.). Asbestos and Mesothelioma. Current Cancer Research. Series ed.: El-Deiry, W. Heidelberg: Springer Verlag, 2017.
Tan Y., Sementino E., Xu J., Pei J., Liu Z., Ito T.K., Cai K.Q., Peri S., Klein-Szanto A.J.P., Wiest D.L., Testa J.R. The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling. Oncotarget 8: 14941-56, 2017. PMCID: PMC5362456
Cheung M., Testa J.R. BAP1 a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res. 6: 270-8, 2017. PMCID: PMC5504107
Tan Y., Sementino E., Chernoff J., Testa J.R. Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. Am J Cancer Res. 7: 1724-37, 2017. PMCID: PMC5574944
Ohar J.A., Cheung M., Talarchek J., Howard S.E., Howard T.D., Hesdorffer M., Peng H., Rauscher F.J., Testa J.R. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res. 76: 206-15, 2016. PMCID: PMC4715907
Kadariya Y., Menges C.W., Talarchek J., Cai Q., Klein-Szanto A.J., Pietrofesa R.A., Christofidou-Solomidou M., Cheung M., Mossman B.T., Shukla A., Testa J.R. Inflammation-related IL-1β/IL-1R signaling promotes the development of asbestos- induced malignant mesothelioma. Cancer Prev Res. 9: 406-14, 2016. PMCID: PMC4854753 [Figure selected for cover photo of journal issue.]
Kadariya Y., Cheung M., Xu J., Pei J., Sementino E., Menges C.W., Cai K.Q., Rauscher F.J., Klein-Szanto A.J., Testa J.R. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76: 2836-44, 2016. PMCID: PMC4873414. [Figure selected for cover photo of journal issue.]
Cheung M., Kadariya Y., Talarchek J., Pei J., Ohar J.A., Kayaleh O.R., Testa J.R. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett. 369: 261-5, 2015. PMCID: PMC4634709
Menges C.W., Kadariya Y., Altomare D.A., Talarchek J., Neumann-Domer E., Wu Y., Xiao G.H., Shapiro I.M., Kolev V.N., Pachter J.A., Klein-Szantos A.J., Testa J.R. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR34a-c-Met axis. Cancer Res. 74: 1261-71, 2014. PMCID: PMC3945416
Shapiro I.M., Kolev V.N., Vidal C.M., Kadariya Y., Ring J.E., Wright Q., Weaver D.T., Menges C., Padval M., McClatchey A.I., Xu Q., Testa J.R., Pachter J.A. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 6: 237ra68, 2014. PMCID: PMC4165339. [Commentary on article appeared in News and Analysis section of JAMA 312: 19, 2014.]
Xu J., Kadariya Y., Cheung M., Pei J., Talarchek J., Sementino E., Tan Y., Menges C.W., Cai K.Q., Litwin S., Peng H., Karar J., Rauscher F.J., Testa J.R. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res. 74: 4388-97, 2014. PMCID: PMC4165574
Carbone M., Yang H., Pass H.I., Krausz T., Testa J.R., Gaudino G. BAP1 and cancer. Nat Rev Cancer. 13: 153-9, 2013. PMCID: PMC3792854
Testa J.R., Cheung M., Pei J., Below J.E., Tan Y., Sementino E., Cox N.J., Dogan A.U., Pass H.I., Trusa S., Hesdorffer M., Nasu M., Powers A., Rivera Z., Comertpay S., Tanji M., Gaudino G., Yang H., Carbone M. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 43: 1022-5, 2011. PMCID: PMC3184199
Altomare D.A., Zhang L., Deng J., Di Cristofano A., Klein-Szanto A.J., Kumar R., Testa J.R. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res. 16: 486-96, 2010. PMCID: PMC2807995 [Article featured in journal Highlights section.]
Tan Y., Timakhov R.A., Rao M., Altomare D.A., Xu J., Liu Z., Gao Q., Jhanwar S.C., Di Cristofano A., Wiest D.L., Knepper J.E., Testa J.R. A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice. Cancer Res. 68: 1296-302, 2008.
Mabuchi S., Altomare D.A., Connolly D.C., Klein-Szanto A., Litwin S., Hoelzle M.K., Hensley H.H., Hamilton T.C., Testa J.R. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. (Priority Report) 67: 2408-13, 2007.
Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., Schilder R.J., Ozols R.F., Testa J.R. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 13: 4261-70, 2007.
Poulikakos P.I., Xiao G.H., Gallagher R., Jablonski S., Jhanwar S.C., Testa J.R. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 25: 5960-8, 2006
Altomare D.A., Vaslet C.A., Skele K.L., De Rienzo A., Devarajan K., Jhanwar S.C., McClatchey A.I., Kane A.B., Testa J.R. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. (Priority Report) 65: 8090-5, 2005.
Xiao G.H., Beeser A., Chernoff J., Testa J.R. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem. 277: 883-6, 2002.
Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., Testa J.R. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 93: 3636-41, 1996.
Bianchi A.B., Mitsunaga S.I., Cheng J.Q., Klein W.M., Jhanwar S.C., Seizinger B., Kley N., Klein-Szanto A.J.P., Testa J.R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA. 92: 10854-8, 1995
Cheng J.Q., Jhanwar S.C., Klein W.M., Bell D.W., Lee W.C., Altomare D.A., Nobori T., Olopade O.I., Buckler A.J., Testa J.R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54: 5547-51, 1994.
Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA. 89: 9267-71, 1992.
Bellacosa A., Testa J.R., Staal S.P., Tsichlis P.N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 254: 274-7, 1991.
Staal S.P., Huebner K., Croce C.M., Parsa N.Z., Testa J.R. The AKT1 proto-oncogene maps to human chromosome 14, band q32. Genomics. 2: 96-8, 1988
Collapse